PL3062811T3 - Interwencje oparte na angiopoetynie do leczenia malarii mózgowej - Google Patents

Interwencje oparte na angiopoetynie do leczenia malarii mózgowej

Info

Publication number: PL3062811T3
Authority: PL; Poland
Prior art keywords: angiopoietin; cerebral malaria; treating cerebral; based interventions; interventions
Prior art date: 2013-11-01

Application number

PL14800207T

Other languages

English (en)

Inventor

Ngambo Lisa Arleen Purcell

Sarah J Higgins

Kevin C Kain

Original Assignee

Regeneron Pharma

Univ Health Network Uhn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-01

Filing date

2014-10-31

Publication date

2019-10-31

2014-10-31 Application filed by Regeneron Pharma, Univ Health Network Uhn filed Critical Regeneron Pharma

2019-10-31 Publication of PL3062811T3 publication Critical patent/PL3062811T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Vascular Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Heart & Thoracic Surgery (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Cardiology (AREA)
Virology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL14800207T 2013-11-01 2014-10-31 Interwencje oparte na angiopoetynie do leczenia malarii mózgowej PL3062811T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201361898539P	2013-11-01	2013-11-01
US201462040514P	2014-08-22	2014-08-22
PCT/US2014/063347 WO2015066426A2 (en)	2013-11-01	2014-10-31	Angiopoietin-based interventions for treating cerebral malaria
EP14800207.4A EP3062811B1 (en)	2013-11-01	2014-10-31	Angiopoietin-based interventions for treating cerebral malaria

Publications (1)

Publication Number	Publication Date
PL3062811T3 true PL3062811T3 (pl)	2019-10-31

Family

ID=51932597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL14800207T PL3062811T3 (pl)	2013-11-01	2014-10-31	Interwencje oparte na angiopoetynie do leczenia malarii mózgowej

Country Status (20)

Country	Link
US (4)	US9592271B2 (pl)
EP (1)	EP3062811B1 (pl)
JP (1)	JP2016537416A (pl)
KR (1)	KR20160099085A (pl)
CN (1)	CN105873599A (pl)
AU (1)	AU2014342162B2 (pl)
CA (1)	CA2928852A1 (pl)
CY (1)	CY1121710T1 (pl)
DK (1)	DK3062811T3 (pl)
ES (1)	ES2727532T3 (pl)
HR (1)	HRP20191070T1 (pl)
HU (1)	HUE044660T2 (pl)
LT (1)	LT3062811T (pl)
MX (1)	MX377089B (pl)
PL (1)	PL3062811T3 (pl)
PT (1)	PT3062811T (pl)
RS (1)	RS59000B1 (pl)
SI (1)	SI3062811T1 (pl)
SM (1)	SMT201900295T1 (pl)
WO (1)	WO2015066426A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2007237096C1 (en)	2006-04-07	2012-12-13	EyePoint Pharmaceuticals, Inc.	Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US7622593B2 (en)	2006-06-27	2009-11-24	The Procter & Gamble Company	Human protein tyrosine phosphatase inhibitors and methods of use
AU2010271105C1 (en)	2009-01-12	2014-08-21	Aerpio Therapeutics, Inc.	Compounds, compositions, and methods for preventing metastasis of cancer cells
MX363351B (es)	2011-10-13	2019-03-20	Aerpio Therapeutics Inc	Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
US20150050277A1 (en)	2013-03-15	2015-02-19	Aerpio Therapeutics Inc.	Compositions and methods for treating ocular diseases
AU2014342162B2 (en)	2013-11-01	2020-01-02	Regeneron Pharmaceuticals, Inc.	Angiopoietin-based interventions for treating cerebral malaria
CN106456614A (zh)	2014-03-14	2017-02-22	爱尔皮奥治疗有限公司	HPTP‑β抑制剂
CA2998673C (en)	2015-09-23	2023-12-12	Aerpio Therapeutics, Inc.	Methods of treating intraocular pressure with activators of tie-2
US10588940B2 (en)	2015-11-06	2020-03-17	Regeneron Pharmaceuticals, Inc.	Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
US20220010281A1 (en)	2018-10-29	2022-01-13	Ottawa Hospital Research Institute	Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
WO2020159444A1 (en) *	2019-01-30	2020-08-06	Agency For Science, Technology And Research	Use of igfbp7 for treating malaria
CA3138682A1 (en)	2019-04-29	2020-11-05	EyePoint Pharmaceuticals, Inc.	Tie-2 activators targeting the schlemm's canal
CN110687289B (zh) *	2019-10-17	2023-04-18	中国人民解放军陆军军医大学	Fgl2蛋白作为疟疾感染标志物的应用
JP2023515827A (ja) *	2020-02-28	2023-04-14	ノースウェスタンユニバーシティ	房水流出を高め、眼圧を減少させる方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1025193A (en)	1911-03-01	1912-05-07	Oliver Jefferson Kennedy	Foldable holder for writing-pads.
JP4493854B2 (ja)	1998-12-23	2010-06-30	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	リガンドの生物学的活性を増強する方法
WO2006035319A2 (en) *	2004-09-28	2006-04-06	Genexel-Sein, Inc.	Methods of using chimeric coiled-coil molecule
US20070154482A1 (en)	2005-09-12	2007-07-05	Beth Israel Deaconess Medical Center	Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
US20120189635A1 (en)	2009-07-29	2012-07-26	Regeneron Pharmaceuticals, Inc.	Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) *	2009-07-29	2018-03-08	Regeneron Pharma	مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
WO2011093851A1 (en) *	2010-01-26	2011-08-04	Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation	Method for treatment of vascular hyperpermeability
ES2694411T3 (es)	2011-08-19	2018-12-20	Regeneron Pharmaceuticals, Inc.	Anticuerpos anti-Tie2 y usos de los mismos
AU2014342162B2 (en)	2013-11-01	2020-01-02	Regeneron Pharmaceuticals, Inc.	Angiopoietin-based interventions for treating cerebral malaria

2014
- 2014-10-31 AU AU2014342162A patent/AU2014342162B2/en not_active Ceased
- 2014-10-31 SI SI201431185T patent/SI3062811T1/sl unknown
- 2014-10-31 PL PL14800207T patent/PL3062811T3/pl unknown
- 2014-10-31 RS RS20190841A patent/RS59000B1/sr unknown
- 2014-10-31 MX MX2016005446A patent/MX377089B/es active IP Right Grant
- 2014-10-31 LT LTEP14800207.4T patent/LT3062811T/lt unknown
- 2014-10-31 JP JP2016552251A patent/JP2016537416A/ja active Pending
- 2014-10-31 ES ES14800207T patent/ES2727532T3/es active Active
- 2014-10-31 EP EP14800207.4A patent/EP3062811B1/en active Active
- 2014-10-31 PT PT14800207T patent/PT3062811T/pt unknown
- 2014-10-31 HU HUE14800207 patent/HUE044660T2/hu unknown
- 2014-10-31 US US14/529,677 patent/US9592271B2/en active Active
- 2014-10-31 KR KR1020167014463A patent/KR20160099085A/ko not_active Withdrawn
- 2014-10-31 WO PCT/US2014/063347 patent/WO2015066426A2/en active Application Filing
- 2014-10-31 CA CA2928852A patent/CA2928852A1/en not_active Abandoned
- 2014-10-31 CN CN201480058778.6A patent/CN105873599A/zh active Pending
- 2014-10-31 SM SM20190295T patent/SMT201900295T1/it unknown
- 2014-10-31 DK DK14800207.4T patent/DK3062811T3/da active
2017
- 2017-01-25 US US15/414,925 patent/US9968653B2/en not_active Expired - Fee Related
2018
- 2018-04-10 US US15/949,472 patent/US10251938B2/en not_active Expired - Fee Related
2019
- 2019-02-21 US US16/282,199 patent/US10525106B2/en not_active Expired - Fee Related
- 2019-05-06 CY CY20191100475T patent/CY1121710T1/el unknown
- 2019-06-13 HR HRP20191070TT patent/HRP20191070T1/hr unknown

Also Published As

Publication number	Publication date
HUE044660T2 (hu)	2019-11-28
MX2016005446A (es)	2017-01-05
JP2016537416A (ja)	2016-12-01
SI3062811T1 (sl)	2020-07-31
US20180228870A1 (en)	2018-08-16
LT3062811T (lt)	2019-05-10
US20190175699A1 (en)	2019-06-13
EP3062811B1 (en)	2019-04-03
AU2014342162A1 (en)	2016-05-26
SMT201900295T1 (it)	2019-07-11
HRP20191070T1 (hr)	2019-09-20
KR20160099085A (ko)	2016-08-19
US10251938B2 (en)	2019-04-09
EP3062811A2 (en)	2016-09-07
PT3062811T (pt)	2019-06-11
CY1121710T1 (el)	2020-07-31
US9592271B2 (en)	2017-03-14
CN105873599A (zh)	2016-08-17
US20170136090A1 (en)	2017-05-18
US10525106B2 (en)	2020-01-07
WO2015066426A2 (en)	2015-05-07
RS59000B1 (sr)	2019-08-30
WO2015066426A3 (en)	2015-07-23
MX377089B (es)	2025-03-07
US9968653B2 (en)	2018-05-15
DK3062811T3 (da)	2019-05-13
CA2928852A1 (en)	2015-05-07
AU2014342162B2 (en)	2020-01-02
US20160045566A1 (en)	2016-02-18
ES2727532T3 (es)	2019-10-16

Publication	Publication Date	Title
IL268987B (en)	2021-01-31	Glaucoma treatment system
SMT201900295T1 (it)	2019-07-11	Interventi a base di angiopoietina per il trattamento della malaria cerebrale
EP3050780A4 (en)	2016-11-02	STEERING APPARATUS
EP3018032A4 (en)	2016-06-15	STEERING DEVICE
GB201312991D0 (en)	2013-09-04	Process
RS63629B1 (sr)	2022-10-31	Aparat
PL3074449T3 (pl)	2017-11-30	Związki addycyjne poliamin
HK1196811A1 (zh)	2014-12-24	電梯設備
GB201307334D0 (en)	2013-05-29	Process
PL3072117T3 (pl)	2019-02-28	Sposób frakcjonowania materiałów lignocelulozowych
HUP1300280A2 (en)	2014-11-28	Equipment for increase arm-muscles
GB2520163B (en)	2018-01-10	Fall prevention apparatus
GB201313915D0 (en)	2013-09-18	Process
HK1173029A2 (en)	2013-05-03	Fastening apparatus
GB201314334D0 (en)	2013-09-25	Process
GB201307327D0 (en)	2013-05-29	Process
GB201302441D0 (en)	2013-03-27	Process
GB201316253D0 (en)	2013-10-30	Process
GB201307951D0 (en)	2013-06-12	Process
GB201300073D0 (en)	2013-02-20	Process
GB201314561D0 (en)	2013-09-25	Process
GB201314674D0 (en)	2013-10-02	Brake apparatus
GB201419631D0 (en)	2014-12-17	Biomarkers for traumatic brain injury
GB201306686D0 (en)	2013-05-29	Fall prevention apparatus
GB201304447D0 (en)	2013-04-24	Fall prevention apparatus